Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Bill-Axelson

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute. Monographs|December 29, 2012
Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waitingLars Holmberg, Anna Bill-Axelson, Gunnar Steineck, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2012
Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe SwedenAndreas Thorstenson, Ola Bratt, Olof Akre, et al.
Journal of the National Cancer Institute|April 5, 2007
Prostate-specific antigen levels as a predictor of lethal prostate cancerKatja Fall, Hans Garmo, Ove Andrén, et al.
Nutrition and Cancer|December 12, 2013
Dietary patterns and prostate cancer risk: report from the population based ULSAM cohort study of Swedish menErika Ax, Hans Garmo, Birgitta Grundmark, et al.
Scandinavian Journal of Urology|June 22, 2017
Additional value of magnetic resonance-targeted biopsies to standard transrectal ultrasound-guided biopsies for detection of clinically significant prostate cancerCatrin von Below, Cecilia Wassberg, Mona Norberg, et al.
European Urology|March 8, 2013
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trialAnna Bill-Axelson, Hans Garmo, Lars Holmberg, et al.
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
BMJ Open|December 29, 2022
Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort studyMats Steinholtz Ahlberg, Hans Garmo, Hans-Olov Adami, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute. Monographs|December 29, 2012
Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waitingLars Holmberg, Anna Bill-Axelson, Gunnar Steineck, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2012
Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe SwedenAndreas Thorstenson, Ola Bratt, Olof Akre, et al.
Journal of the National Cancer Institute|April 5, 2007
Prostate-specific antigen levels as a predictor of lethal prostate cancerKatja Fall, Hans Garmo, Ove Andrén, et al.
Nutrition and Cancer|December 12, 2013
Dietary patterns and prostate cancer risk: report from the population based ULSAM cohort study of Swedish menErika Ax, Hans Garmo, Birgitta Grundmark, et al.
Scandinavian Journal of Urology|June 22, 2017
Additional value of magnetic resonance-targeted biopsies to standard transrectal ultrasound-guided biopsies for detection of clinically significant prostate cancerCatrin von Below, Cecilia Wassberg, Mona Norberg, et al.
European Urology|March 8, 2013
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trialAnna Bill-Axelson, Hans Garmo, Lars Holmberg, et al.
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
BMJ Open|December 29, 2022
Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort studyMats Steinholtz Ahlberg, Hans Garmo, Hans-Olov Adami, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Pageof 9